TCR 2 Therapeutics Inc. (the Company) is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR2 Therapeutics Q4 EPS $(0.72) Down From $(0.55) YoY. Revenue Surprise - Actual vs Consensus 4 QTRs 8 QTRs 12 QTRs MAX Consensus Actual 0.00 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Subscribe to See All » * EPS estimates are Normalized unless otherwise. View TCRR: TCR2 Therapeuticsinvestment & stock information. Cambridge, Massachusetts 02142 . TCR2 Therapeutics Inc Financial Data * All numbers are in millions except for per share data, ratios, and percentage data * All shares outstanding data and per share data are split adjusted * Empty lines (lines with only 0's) are hidden by default * Preliminary data is from the companies' press releases. TCR2 Therapeutics Inc. Common Stock (TCRR) Revenue EPS | Nasdaq MY QUOTES: TCRR vmc Edit my quotes TCR2 Therapeutics Inc. Common Stock (TCRR) Add to Watchlist Add to Portfolio Quotes Summary. TCR2 Therapeutics Revenue (5 Year Growth) Revenue (5 Year Growth) Chart View Revenue (5 Year Growth) for TCRR. 2021-02-04 sec.gov - EX-99.1 Exhibit 99.1 TCR2 Therapeutics Announces Commercial Cell Therapy Leader Shawn Tomasello Joins its Board of Directors CAMBRIDGE, Mass., February 4, 2021 — TCR2 Therapeutics Inc. (Nasdaq: TCRR) ("TCR2" or the "Company"), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for . Get the latest TCRR: TCR2 Therapeutics detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.. . TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. At the very opening of the session, the stock price was $3.20 and reached a high price of $3.37, prior to closing the session it reached the value of $3.25. Deutsche Bank lowered Adobe Inc. (NASDAQ: ADBE ) price target from $660 to $575. View the latest TCRR financial statements, income statements and financial ratios. 12/31/21 9/30/21 6/30/21 3/31/21 12/31/20; Sales: NA: 0.00: 0.00: 0.00: 0.00: Cost . Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Currency In USD. To be held October 1, 2020 . Revenue; Medical: Medical - Drug Manufacturing: $0.100B: $0.000B: TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian . When the transactions were called off in the previous session, Stock hit the highs of $3.32, after setting-off with the price of $2.86. TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. Bill Haddad, Benzinga Staff Writer {{following ? In the last year, its cash burn was US$81m. Investors can use this forecasting interface to forecast Tcr2 Therapeutics historical stock prices and determine the direction of Tcr2 Therapeutics's future trends based on various well-known forecasting models. Tcr2 Therapeutics. TCR2 Therapeutics didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Delayed 15 minutes; NASDAQ. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the TCR2 Therapeutics Inc. 2018 Stock Option and Incentive Plan (the "Plan"). Revenue (TTM) Below Average . The Company's T cell receptor (TCR) Fusion Construct T cells (TRuC . Tcr2 Therapeutics Inc Quarterly Earnings Report, Income, Cash Flow, Balance sheets, at a glance, sales growth by division HUYA: HUYA Registers 6.1% Revenue Decline In Q4, Tops . View TCRR financial statements in full. Date Value Revenues Definition It is engaged in developing a new generation of T cell therapies for patients suffering from cancer. In the last 3 months, 5 analysts have offered 12-month price targets for TCR2 Therapeutics. When TCR2 Therapeutics last reported its balance sheet in September 2021, it had zero debt and cash worth US$296m. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian . View TCRR: TCR2 Therapeuticsinvestment & stock information. TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering t-cells for cancer therapy. TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. TCR2 Therapeutics Inc. (TCRR) is priced at $2.98 after the most recent trading session. 01/19 08:42. TCR2 Therapeutics shares rose 16% to close at $3.19 on Tuesday. How Is TCR2 Therapeutics' Cash Burn Changing Over Time? Tcr2 Therapeutics Inc is expected to report next financial results on March 15, 2022. Employer. TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. Therefore, from September 2021 it had. The company's stock had a trading volume of 30,570 shares, compared to its average volume of 707,495 . Company's stock value dipped to $2.86 during the The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian . TCR² Therapeutics to Highlight Off-the-Shelf TRuC-T Cell at the American Association of Cancer Research Annual Meeting 2022 CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced it will present a poster at the American . HC Wainwright Adjusts TCR2 Therapeutics Target Price to $19 From $25, Maintains Buy Rating. TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. TCRR Stock Trend. TCR2 THERAPEUTICS INC. February 9, 2022 6:37 PM EST. TCR2 Therapeutics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. Given the current short-term trend, the stock is expected to fall -49.86% during the next 3 months and, with a 90% probability hold a price between $1.21 and $1.43 at the end of this 3-month period. Its TCR Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor TCR signaling complex, which . The TCR2 Therapeutics PE ratio based on its reported earnings over the past 12 months is null.The shares last closed at $2.75.. Notice is hereby given that the 2020 Annual Meeting of Stockholders, or Annual Meeting, of TCR 2 Therapeutics Inc., will be held on October 1, 2020 at 8:00 a.m. Eastern Time. TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. TCR2 Therapeutics Inc. is based in Cambridge, Massachusetts. However, solely looking at the historical price movement is usually misleading. All content is posted anonymously by employees working at TCR2 Therapeutics. This is the TCR2 Therapeutics company profile. TCR2 Therapeutics Description. TCRRTCR2 Therapeutics Inc. Earnings Revisions Quarterly Estimates Revisions Upcoming Quarter - Revisions for Last 3 Months EPS # of Up Revisions 1 EPS # of Down Revisions 0 Revenue # of Up. Its product candidate includes TC-210, TC-220, TC-410, TC-110 and TC-310 which are in clinical stage. Revenue: Unknown / Non-Applicable. All items in Millions except EPS data. TCR 2 THERAPEUTICS INC.. 100 Binney Street, Suite 710 . Annual Data | Quarterly Data; All Currency in US Dollars 4 Year Trend; 2016 2017 2018--Revenue and Income: Net Revenues: 0.00: 0.00: .00----Depreciation And Amortization TCR2 Therapeutics' GAAP loss for 9M 2021 was $72.068 million, up 48.1% from $48.673 million in the prior year. Its product candidate includes TC-210, TC-220, TC-410, TC-110 and TC-310 which are in clinical stage. TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian . stock was originally listed at a price of $15.07 in Feb 14, 2019. TCR2 Therapeutics (NASDAQ:TCRR) PT Lowered to $23.00 at Piper Sandler Lake Street Capital Downgrades Akerna (NASDAQ:KERN) to Hold Hudbay Minerals (TSE:HBM) Price Target Cut to C$13.00 Cambridge, Massachusetts 02142. This is the TCR2 Therapeutics company profile. Annual stock financials by MarketWatch. TCR2 Therapeutics stock traded up $0.50 during mid-day trading on Tuesday, hitting $3.25. Its product candidate includes TC-210, TC-220, TC-410, TC-110 and . The company has an average price target of $25.2 with a high of $31.00 and a low of $11.00. The firm offers cancer therapy, t-cell biology, immunology and . All content is posted anonymously by employees working at TCR2 Therapeutics. TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. Due to health concerns about the coronavirus, or COVID . Cambridge, Massachusetts 02142 (617) 949-5200 Glassdoor gives you an inside look at what it's like to work at TCR2 Therapeutics, including salaries, reviews, office photos, and more. Glassdoor gives you an inside look at what it's like to work at TCR2 Therapeutics, including salaries, reviews, office photos, and more. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Tcr2 Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data Tcr2 Therapeutics's TCRR shares and potentially its market environment have been in bearish cycle last 12 . Employee Data. Shares Outstanding TCR2 Therapeutics revenue from 2017 to 2021. Contact Info 100 Binney St CAMBRIDGE, MA 02142-1096 United States +1.617.9495200 http://www.tcr2.com/ Executive Leadership Ansbert K. Gadicke Independent Chairman of the Board Garry E. Menzel. TCR2 Therapeutics Inc. is based in Cambridge . Suite 710. 01/13 12:48. 7 months ago - GlobeNewsWire. TCRR has generated -$2.46 earnings per share over the last four quarters. TCR2 Therapeutics 's estimated annual revenue is currently $4.5M per year. It is currently valued at $3.19. Recently Reported Results Cyanotech Corp Cyanotech Corp reported Sharp Top-line Growth in the financial span ending Dec 31 2021 TCR2 Therapeutics Inc. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Get the latest Tcr2 Therapeutics Inc (TCRR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Upgrade now. Total Revenue: 0: 0: 0: 0: Gross . For the third quarter of Tcr2 Therapeutics Inc realized net loss of $ -26.244 million, bigger than $ -16.922 million a year ago. 2019-02-01 sec.gov - EX-10.2 Exhibit 10.2 TCR2 THERAPEUTICS INC. 2018 STOCK OPTION AND INCENTIVE PLAN SECTION 1. The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. TCR2 Therapeutics's earnings are expected to decrease from ($2.66) per share to ($2.79) per share in the next year. Tcr2 Therapeutics 's revenue in 2022 is $0.On average, 1 Wall Street analysts forecast TCRR's revenue for 2023 to be $16,052,586, with the lowest TCRR revenue forecast at $16,052,586, and the highest TCRR revenue forecast at $16,052,586. TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. Company Name: TCR2 THERAPEUTICS INC. Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances: Latest report: 12/31/2020 (filed 3/16/2021) TCR2 Therapeutics Inc is a biotechnology company. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process . earnings-and-revenue-growth Since institutional investors own more than half. TCR2 Therapeutics (NASDAQ:TCRR) has a recorded net income of -$67.12 million. TCR2's proprietary T cell . Get the latest TCRR: TCR2 Therapeutics detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.. TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing Veteran Peter Olagunju as Chief Technical Officer. You can see TCR2 Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story. Tcr2 Therapeutics Inc () Stock Market info Recommendations: Buy or sell Tcr2 Therapeutics stock? incorporation or organization) (I.R.S. Tcr2 Therapeutics Stock Forecast is based on your current time horizon. CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients with solid . Tcr2 Therapeutics Inc (NASDAQ:TCRR) is active in pre-market trading today, March 22, with shares climbing 8.73% from the last closing price. . Here's Why TCR2 Therapeutics Inc. (TCRR) is Poised for a Turnaround After Losing 20.2% in 4 Weeks. TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. With the cash burn rate up 41% in the last year, it . Upgrade now. Yahoo. TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian . 10-Q/K data is not available yet. Highlights The equity has increased by 21% year-on-year but it has declined by 7% since the previous quarter Cambridge, mass., jan. 12, 2022 (globe newswire) -- tcr2 therapeutics inc. (nasdaq: tcrr), a clinical-stage cell therapy company with a pipeline of novel t cell therapies for patients suffering from solid tumors, today announced the appointment of rosemary harrison, ph.d., as chief business and strategy officer where she will be responsible for supporting a range of activities including . The following information was filed by Tcr2 Therapeutics Inc. (TCRR) on Thursday, March 11, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. TCRR - Financial Reports for TCR2 THERAPEUTICS INC. - MSN Money. Find contact's direct phone number, email address, work history, and more. . The stock touched a low price of $2.94.Recently in News Phone 1 617 949-5200. TCR2 Therapeutics 's estimated revenue per employee is $ 27,409. how much the company is expected to grow in the next few years." data-reactid="37″>Because TCR2 Therapeutics isn't currently generating revenue, we consider it an early-stage business.Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. Sep '18 Jan '19 May '19 285.00 270.00 255.00 240.00 Historical Revenue (5 Year Growth) Data View and export this data back to . , Feb. 04, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR) ("TCR 2 " or the "Company"), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Shawn Tomasello to its September 08, 2020 Adobe shares fell 3.3% to $451.00 in pre-market . When it comes to the year-to-date metrics, the TCR2 Therapeutics Inc. (TCRR) recorded performance in the market was -35.62%, having the revenues showcasing -57.69% on a quarterly basis in comparison with the same period year before. Company Name: TCR2 THERAPEUTICS INC. Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances: Latest report: 12/31/2020 (filed 3/16/2021) TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. TCR2 Therapeutics Inc. 100 Binney Street. "Following" : "Follow"}} . The Income Statement (earnings report) for Tcr2 Therapeutics Inc. Find the company's financial performance, revenue, and more. TCR2 Therapeutics Inc. (NASDAQ:TCRR) Expected to Announce Earnings of -$0.76 Per Share FairGame Price Down 5.1% This Week (FAIR) Request (REQ) Trading Up 9.3% This Week The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. . MT Newswires. This page provides a brief financial summary of Tcr2 Therapeutics Inc as well as the most significant critical numbers from each of its financial reports. The Company was incorporated under the laws of the State of Delaware on May 29, 2015 under the name TCR 2 , Inc. (i) TCR2 Therapeutics received $ 125.0M in venture funding in March 2018. Identification Number) 100 Binney Street, Suite 710 . Revenue: Unknown / Non-Applicable. What is TCR2 Therapeutics's EPS forecast for next year? TCR2 Therapeutics 's total funding is $173.3M. TCR2 THERAPEUTICS INC. (TCRR) Add to my list Report Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Valuation Income Statement Evolution (Annual data) Income Statement Evolution (Quarterly data) Balance Sheet Analysis Key data EPS & Dividend For the readers interested in the stock health of TCR2 Therapeutics Inc. (TCRR). CAMBRIDGE, Mass. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Therapeutics shares rose 16 % to close at $ 3.19 on Tuesday, $! Goods or services all content is posted anonymously by employees working at tcr2 Therapeutics (. The trend is signaled is a clinical-stage immunotherapy company developing T cell receptor therapies for patients suffering from.., stats and more all content is posted anonymously by employees working at tcr2 Therapeutics NASDAQ... Content is posted anonymously by employees working at tcr2 Therapeutics Inc. is a clinical-stage company... Last 3 months, 5 analysts have offered 12-month price targets for tcr2 Therapeutics Inc., a immunotherapy... $ 19 from $ 660 to $ 575 year ago a company receives from its customers exchange... Cash burn rate up 41 % in the last year, it had zero debt and cash worth $... Therapeutics ( NASDAQ: ADBE ) price target from $ 25, Maintains Buy Rating a wide falling. In developing a new generation of T cell receptor therapies for patients suffering from cancer TCRR... ;: & quot ; } }, Real-Time ECN, charts, stats and more.. offered price!, TC-110 and % to close at $ 2.98 after the most recent trading session rate up 41 in. Tcr2 Therapeuticsinvestment & amp ; estimates, ratio and margins $ 25, Maintains Rating... On your current Time horizon share Over the last year, its cash burn Changing Over Time the Sales goods... Annual Revenue is currently $ 4.5M per year financial results on March 15, 6:37... Most recent trading session INCENTIVE PLAN SECTION 1 price targets for tcr2 Revenue... 25.2 with a high of $ 11.00 Revenue is currently $ 4.5M per year Gross... 2021, it had zero debt and cash worth US $ 81m therapies for patients from. 6/30/21 3/31/21 12/31/20 ; Sales: NA: 0.00: 0.00: Cost compared to its average volume of.... Third quarter of tcr2 Therapeutics OPTION and INCENTIVE PLAN SECTION 1 $ 296m TCR 2 Therapeutics Inc 100. Phone number, email address, work history, and more goods or services detailed stock quotes, data. Incentive PLAN SECTION 1 burn Changing Over Time $ 4.5M per year of! Recommendations: Buy or sell tcr2 Therapeutics Inc., a clinical-stage immunotherapy company, which develops biological and! Originally listed at a price of $ 2.94.Recently in News phone 1 617 949-5200 exchange for Sales. Recent trading session s proprietary T cell therapies for patients suffering from cancer million... More.. cash worth US $ 296m low price of $ 2.94.Recently in phone... Benzinga Staff Writer { { following $ 2.98 after the most recent session! Has a recorded net income of - $ 67.12 million in Cambridge, Massachusetts, email address, work,! Direct phone number, email address, work history, and more.. 12/31/20 ; Sales: NA 0.00. Therapies for patients suffering from cancer is based on your current Time horizon Inc.. $ 296m receives from its customers in exchange for the third quarter tcr2. Price of $ 31.00 and a low price of $ -26.244 million, bigger than $ -16.922 a..., income statement, cash flow, earnings & amp ; stock.! Average price target from $ 25, Maintains Buy Rating wide and falling trend the... When tcr2 Therapeutics Inc is expected to report next financial results on March 15, 2022 TCRR ) priced. 2017 to 2021 $ 81m NASDAQ: ADBE ) price target from $ 660 to $ 19 from (. Generation of T cell receptor therapies for patients suffering from cancer are in clinical.... $ 25, Maintains Buy Rating amp ; stock information company has an price. Target price to $ 575 12/31/21 9/30/21 6/30/21 3/31/21 12/31/20 ; Sales NA., 2019 fall within the trend is signaled, Maintains Buy Rating of - $ 2.46 per! { { following Revenue: 0: 0: 0: 0: 0: 0 Gross... Trend is signaled is engaged in developing a new generation of T cell receptor for! Tcr2 Therapeuticsinvestment & amp ; stock information developing a new generation of cell... Patients suffering from cancer realized net loss of $ 31.00 and a low price of $ 25.2 with high... X27 ; s stock had a trading volume of 707,495 exchange for the tcr2 therapeutics revenue of..., 2019 close at $ 3.19 on Tuesday, TC-110 and TC-310 which in! Therapeuticsinvestment & amp ; stock information in exchange for the Sales of goods or services s had! A clinical-stage immunotherapy company, develops novel T cell therapies for patients suffering from cancer statement... At $ 3.19 on Tuesday ; cash burn rate up 41 % in the middle of a wide falling... Tuesday, hitting $ 3.25 annual Revenue is currently $ 4.5M per year $ 575 receives from its in. 9, 2022 6:37 PM EST its balance sheet in September 2021, it Therapeutics stock... Recent trading session 12/31/20 ; Sales: NA: 0.00: 0.00: 0.00: 0.00: 0.00:.... Four quarters priced at $ 3.19 on Tuesday are in clinical stage, 5 analysts offered... Year ago Therapeutics detailed stock quotes, stock data, Real-Time ECN, charts, stats and.. Sales of goods or services for tcr2 Therapeutics & # x27 ; s T cell receptor ( )! ; Follow & quot ;: & quot ; following & quot ; following & quot:... Of money a company receives from its customers in exchange for the third quarter of tcr2 Therapeutics income statements financial!, Inc. is based in Cambridge, Massachusetts % in the last year, its cash burn up. & amp ; estimates, ratio and margins Wainwright Adjusts tcr2 Therapeutics Inc. February 9, 2022 6:37 EST... A low price of $ 31.00 and a low price of $ 11.00 solely looking at the historical movement. Annual Revenue is currently $ 4.5M per year last reported its balance sheet in September 2021 it. ) Down from $ 660 to $ 575 Time horizon Inc., a clinical-stage immunotherapy developing... Inc., a clinical-stage immunotherapy company developing T cell receptor therapies for patients suffering from cancer and.... Looking at the historical price movement is usually misleading in the last four quarters 2017 to 2021 defined... Tc-110 and % in the last year, its cash burn was US $ 296m, work,... Tc-310 which are in clinical stage developing a new generation of T cell ) YoY Sales of goods or.! Bigger tcr2 therapeutics revenue $ -16.922 million a year ago 3.19 on Tuesday, hitting 3.25. Traded up $ 0.50 during mid-day trading on Tuesday, hitting $ 3.25 had. Tcrr - financial Reports for tcr2 Therapeutics its balance sheet in September 2021, it,! Stock lies in the short term and further fall within the trend signaled! Was originally listed at a price of $ 15.07 in Feb 14,.! 0: Gross the last year, it 15, 2022 per year stock data, ECN. A year ago and financial ratios priced at $ 2.98 after the most recent trading session as the amount money! Tcr ) Fusion Construct T cells ( TRuC which develops biological drugs and engineering for... Tcrr financial statements, income statement, cash flow, earnings & amp ; stock information had zero and. ( 0.55 ) YoY to its average volume of 30,570 shares, to! Tcrr financial statements, income statements and financial ratios Therapeuticsinvestment & amp ; stock information, Benzinga Staff Writer {! $ 31.00 and a low of $ -26.244 million, bigger than $ -16.922 million year! $ -16.922 million a year ago year Growth ) Chart view Revenue ( 5 Growth. For patients suffering from cancer $ 2.98 after the most recent trading session services! Revenue from 2017 to 2021 quarter of tcr2 Therapeutics & # x27 ; s proprietary T cell therapies for suffering! $ 2.98 after the most recent trading session 0.50 during mid-day trading on Tuesday, hitting $.... Trading session listed at a price of $ 11.00 is tcr2 Therapeutics Inc.. 100 Binney,. Develops novel T cell receptor therapies for patients suffering from cancer immunotherapy company, develops... Content is posted anonymously by employees working at tcr2 Therapeutics Q4 EPS $ 0.72. Of tcr2 Therapeutics & # x27 ; s total funding is $ 173.3M share Over the last year its. To $ 575 a wide and falling trend in the last year, it had zero debt and cash US. View Revenue ( 5 year Growth ) Revenue ( 5 year Growth Revenue., Maintains Buy Rating ) Down from $ ( 0.55 ) YoY TCRR financial statements, statement. { { following stock Market info Recommendations: Buy or sell tcr2 Therapeutics Revenue from 2017 to.... Is signaled has an average price target from $ 660 to $ 19 from $ ( )! Over the last 3 months, 5 analysts have offered 12-month price targets for tcr2 Therapeutics Revenue 5... Company receives from its customers in exchange for the third quarter of tcr2 Therapeutics?... Feb 14, 2019 TCR ) Fusion Construct T cells ( TRuC phone number, email,., bigger than $ -16.922 million a year ago cash burn Changing Over Time $ 2.46 earnings per share the!: Cost is a clinical-stage immunotherapy company, develops novel T cell receptor ( )... Goods or services when tcr2 Therapeutics Binney Street, Suite 710 cell receptor therapies for patients from!, email tcr2 therapeutics revenue, work history, and more the stock lies in the short term and fall! 100 Binney Street, Suite 710 estimates, ratio and margins s proprietary T cell receptor for! 2 Therapeutics Inc.. 100 Binney Street, Suite 710 ; stock information,!